Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Trenque

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Therapie|November 21, 2020
Bismuth and pharmacovigilanceThierry Trenque
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 29, 2016
Discrepancy between long-term and previously published analysis for osteonecrosis of the jaw under denosumabPaul de Boissieu, Thierry Trenque
The Lancet. Diabetes & Endocrinology|September 24, 2017
Denosumab treatment in postmenopausal women with osteoporosisPaul de Boissieu, Thierry Trenque
Expert Opinion on Drug Safety|May 7, 2015
Standardized classification unsuitable for spontaneous reporting: the example of osteonecrosis of the jawPaul de Boissieu, Thierry Trenque
Lancet (London, England)|December 25, 2015
Denosumab and fracture risk in women with breast cancerPaul de Boissieu, Thierry Trenque
The Lancet. Oncology|March 6, 2020
Adjuvant denosumab in early breast-cancerPaul de Boissieu, Thierry Trenque
Journal of the American Academy of Dermatology|November 25, 2024
Psoriasis after exposure to angiotensin converting enzyme inhibitors: Clinical features of a signal from the WHO pharmacovigilance databaseBrahim Azzouz, Manuelle Viguier, Thierry Trenque
Therapie|February 25, 2009
[Over the counter medication in pregnant women]Sofia Mikou, Anne-Claire Buire, Thierry Trenque
Frontiers in Pharmacology|September 5, 2022
Anti-NMDA receptor encephalitis and vaccination: A disproportionality analysisSalomé Martin, Brahim Azzouz, Aurore Morel, et al.
Expert Opinion on Drug Safety|December 18, 2020
Drug induced stuttering: pharmacovigilance dataThierry Trenque, Aurore Morel, Agathe Trenque, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Therapie|November 21, 2020
Bismuth and pharmacovigilanceThierry Trenque
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 29, 2016
Discrepancy between long-term and previously published analysis for osteonecrosis of the jaw under denosumabPaul de Boissieu, Thierry Trenque
The Lancet. Diabetes & Endocrinology|September 24, 2017
Denosumab treatment in postmenopausal women with osteoporosisPaul de Boissieu, Thierry Trenque
Expert Opinion on Drug Safety|May 7, 2015
Standardized classification unsuitable for spontaneous reporting: the example of osteonecrosis of the jawPaul de Boissieu, Thierry Trenque
Lancet (London, England)|December 25, 2015
Denosumab and fracture risk in women with breast cancerPaul de Boissieu, Thierry Trenque
The Lancet. Oncology|March 6, 2020
Adjuvant denosumab in early breast-cancerPaul de Boissieu, Thierry Trenque
Journal of the American Academy of Dermatology|November 25, 2024
Psoriasis after exposure to angiotensin converting enzyme inhibitors: Clinical features of a signal from the WHO pharmacovigilance databaseBrahim Azzouz, Manuelle Viguier, Thierry Trenque
Therapie|February 25, 2009
[Over the counter medication in pregnant women]Sofia Mikou, Anne-Claire Buire, Thierry Trenque
Frontiers in Pharmacology|September 5, 2022
Anti-NMDA receptor encephalitis and vaccination: A disproportionality analysisSalomé Martin, Brahim Azzouz, Aurore Morel, et al.
Expert Opinion on Drug Safety|December 18, 2020
Drug induced stuttering: pharmacovigilance dataThierry Trenque, Aurore Morel, Agathe Trenque, et al.
Pageof 6